Ask AI
ADCs in Breast Cancer

CE / CME

Maximizing Efficacy and Minimizing Toxicities With Antibody–Drug Conjugates in Breast Cancer

Nurse Practitioners/Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: October 01, 2025

Expiration: March 31, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

When addressing sacituzumab-related diarrhea, what are the first appropriate steps to safely manage diarrhea of different grades?

2.

A 36-yr-old woman was diagnosed with stage III locally advanced HR+/HER2- (IHC 0) right breast cancer. She proceeded with neoadjuvant ddAC-T. Repeat imaging, prior to surgery and post chemotherapy, showed partial response in her breast but suspicious lung nodules. Biopsy confirmed HR+/HER2- mBC. She started endocrine therapy with ovarian ablation, anastrozole, and CDK4/6 inhibitor. At the time of progression, genomic testing revealed a PIK3CA mutation. After progressing on PI3K inhibitor, what therapy should she start next?

3.

A 63-yr-old woman with HR+/HER2- (IHC 1+, ISH not amplified) mBC previously received 2 lines of endocrine therapy, capecitabine, T-DXd for HER2-ultralow disease. She has no genetic mutations. For her next line of therapy, things to consider include multiple holds and dose reductions due to neutropenia. Based on the adverse effect profiles of the ADCs below, what would you pick for her next line of therapy?

4.

When discussing the unique characteristics of ADCs with patients, which of the following would you tell them about potential for a “bystander effect”?